VTX-2337: Phase Ib data

Data from 13 patients with recurrent or persistent ovarian cancer in 1 arm of an open-label, U.S. Phase Ib trial showed that 2.5, 3 and 3.5 mg/m 2 doses of subcutaneous VTX-2337 on days 3, 10 and 17 of a 28-day cycle in combination with 40 mg/m 2 Doxil doxorubicin on day 1 were well tolerated with no DLTs reported. Of 11 evaluable patients, there was 1 complete response and 63% of patients achieved stable disease. Data from 7 patients in a separate arm showed that 3 mg/m 2 VTX-2337 in combination with 80 mg/m 2 paclitaxel on days 1, 8 and 15 was well tolerated with 43% of patients achieving stable disease. VentiRx is conducting the trial with the Gynecologic Oncology Group. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...